# Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

> **NCT00617591** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Pegylated Liposomal Doxorubicin (PLD)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00617591
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2014-01-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617591, "Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00617591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*